文献速递肿瘤 PET/CT

探索FAP靶向PET/CT在区分乳腺癌分子亚型中的价值:一项初步研究

Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-08-12

这项前瞻性单中心研究连续纳入2023年7月至2024年5月疑似乳腺癌患者53例,均行[18F]AlF-NOTA-FAPI-04 PET/CT。不同分子亚型示踪剂摄取存在差异,SUVmax对luminal A亚型分类AUC=0.912,对luminal B(HER2阴性)AUC=0.770,对三阴性AUC=0.781。结论认为该显像与分子亚型显著相关,有望无创识别luminal A亚型并指导FAP靶向治疗。

要点

  • 53例疑似乳腺癌患者行[18F]AlF-NOTA-FAPI-04 PET/CT,不同分子亚型摄取水平不同。
  • SUVmax区分luminal A亚型AUC=0.912,灵敏度100%、特异度83%。
  • SUVmax区分三阴性亚型AUC=0.781,灵敏度100%、特异度51%。

核心结论

  • [18F]AlF-NOTA-FAPI-04摄取与乳腺癌分子亚型显著相关,PET/CT是潜在的无创识别luminal A亚型及指导FAP靶向治疗的工具。

研究设计与样本

  • 前瞻性单中心研究,连续纳入2023年7月至2024年5月疑似乳腺癌患者53例(平均年龄51±11岁,52例女性),均行[18F]AlF-NOTA-FAPI-04 PET/CT。
  • 比较不同不良预后因素及不同分子亚型乳腺癌的示踪剂摄取差异,并用受试者工作特征(ROC)曲线评估各分子亚型的分类性能。

主要发现

  • 具有不良预后因素的乳腺癌病灶示踪剂摄取较高。
  • 五种分子亚型摄取水平不同:luminal A与luminal B(HER2阴性)摄取相对低,luminal B(HER2阳性)、HER2阳性及三阴性摄取相对高。
  • SUVmax区分luminal A亚型AUC=0.912(P=0.0005),灵敏度100%、特异度83%。
  • SUVmax预测luminal B(HER2阴性)亚型AUC=0.770(P=0.0015)。
  • SUVmax识别三阴性亚型AUC=0.781(P=0.003),灵敏度100%、特异度51%;切点15.40(AUC=0.921,P<0.0001)可区分luminal A与luminal B(HER2阴性)组及luminal B(HER2阳性)、HER2阳性与三阴性组,灵敏度94%、特异度79%。

关键数值与推荐

  • SUVmax区分luminal A亚型:AUC=0.912(P=0.0005),灵敏度100%,特异度83%。
  • SUVmax预测luminal B(HER2阴性)亚型:AUC=0.770(P=0.0015)。
  • SUVmax识别三阴性亚型:AUC=0.781(P=0.003),灵敏度100%,特异度51%。
  • 切点15.40区分luminal A与luminal B(HER2阴性)组及luminal B(HER2阳性)、HER2阳性与三阴性组:AUC=0.921(P<0.0001),灵敏度94%,特异度79%。

临床怎么用

  • 原文结论认为[18F]AlF-NOTA-FAPI-04 PET/CT是潜在的无创识别luminal A亚型及指导FAP靶向治疗的工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study aims to evaluate the value of [18F]AlF-NOTA-fibroblast activation protein inhibitor (FAPI)-04 positron emission tomography-computed tomography (PET/CT) in predicting molecular subtypes of breast cancer. METHODS: The study consecutively recruited patients suspected of having breast cancer from a single center who were prospectively enrolled from July 2023 to May 2024 and underwent [18F]AlF-NOTA-FAPI-04 PET/CT. This study compared the differences in tracer uptake among breast cancers with different adverse prognostic factors and molecular subtypes. The classification performance for each molecular subtype of breast cancer was assessed using a receiver operating characteristic (ROC) curve. RESULTS: Fifty-three participants (mean age, 51 ± 11 years; 52 females) were evaluated. Breast cancer lesions with adverse prognostic factors showed higher tracer uptake. The five different molecular subtypes exhibited varying levels of uptake. The luminal A and luminal B (HER2-negative) subtypes had relatively low uptake, while the luminal B (HER2-positive), HER2-positive, and triple-negative subtypes had relatively high uptake. ROC analysis identified the max standardized uptake value (SUVmax) as a significant classifier (AUC = 0.912, P = 0.0005) for the luminal A subtype, with 100% sensitivity and 83% specificity. For predicting the luminal B (HER2-negative) subtype, SUVmax had an AUC of 0.770 (P = 0.0015). SUVmax, with an AUC of 0.781 (P = 0.003), was used to identify the triple-negative subtype tumors, resulting in a sensitivity of 100% and specificity of 51%. Lastly, the ROC curve showed the cut-off 15.40 (AUC = 0.921, P < 0.0001) could classify luminal A & luminal B (HER2-negative), and luminal B (HER2-positive) & HER2-positive & triple-negative, yielding a sensitivity of 94% and specificity of 79%. CONCLUSION: The uptake of [18F]AlF-NOTA-FAPI-04 is significantly correlated with the molecular subtypes of breast cancer, and [18F]AlF-NOTA-FAPI-04 PET/CT is a potential tool for noninvasive identification of luminal A subtypes and guidance of FAP-targeted therapies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu T, Xu S, Cheng K, et al. Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study. Eur J Nucl Med Mol Imaging. 2024. PMID: 39133307. doi:10.1007/s00259-024-06873-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。